Low specificity of voltage-gated calcium channel antibodies in Lambert–Eaton myasthenic syndrome: a call for caution

3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia

(2018) Donald B. Sanders et al.   MUSCLE & NERVE

Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results

(2017) Hesham Abboud et al.   JOURNAL OF NEUROLOGY

Lambert–Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer

(2017) Benedikt Schoser et al.   JOURNAL OF NEUROLOGY

Paraneoplastic autoantibody panels: sensitivity and specificity, a retrospective cohort

(2016) Rawan Albadareen et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Amifampridine phosphate (Firdapse®) is effective and safe in a phase 3 clinical trial in LEMS

(2016) Shin J Oh et al.   MUSCLE & NERVE

P/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments

(2016) Nicholas L. Zalewski et al.   MUSCLE & NERVE

Clinical experience of seropositive ganglionic acetylcholine receptor antibody in a tertiary neurology referral center

(2015) Yuebing Li et al.   MUSCLE & NERVE

Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine

(2015) Ted M. Burns et al.   MUSCLE & NERVE

Lambert–Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies

(2011) Maarten J Titulaer et al.   LANCET NEUROLOGY

Efficacy of 3,4-Diaminopyridine and Pyridostigmine in the Treatment of Lambert–Eaton Myasthenic Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study

(2009) PW Wirtz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS

(2009) Shin J. Oh et al.   MUSCLE & NERVE